{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T01:58:35Z","timestamp":1777514315086,"version":"3.51.4"},"reference-count":27,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CIMB"],"abstract":"<jats:p>Although ombitasvir\/paritaprevir\/ritonavir plus dasabuvir (OPrD) therapy is highly effective for chronic hepatitis C (CHC), clinicians frequently encounter transient hyperbilirubinemia, which can be misidentified as hepatotoxicity. This study investigated the role of SLCO1B1 (OATP1B1) and SLCO1B3 (OATP1B3) genetic polymorphisms in predicting bilirubin spikes and distinguishing transporter-mediated interference from hepatocellular injury. In this prospective study of 65 patients with HCV genotype 1, genotyping for OATP1B1 (c.388A&gt;G, c.521T&gt;C) and OATP1B3 (c.334T&gt;G, c.699G&gt;A) was performed using PCR-RFLP and capillary electrophoresis (QIAxcel Advanced System). Clinical and biochemical parameters were monitored over a 12-week treatment period. Hyperbilirubinemia (total bilirubin &gt;1.1 mg\/dL) developed in 18.5% of the cohort, typically within the first month. A distinct \u2018AST-dominant\u2019 biochemical signature, elevated bilirubin and AST paired with stable ALT, was identified, suggesting transporter-specific interference rather than hepatocyte damage. Statistical analysis pinpointed the OATP1B3 c.699G&gt;A (rs7311358) variant as the sole genetic driver (p = 0.007). Carriers of the c.699G&gt;A allele faced a 6.3-fold higher risk of developing hyperbilirubinemia (OR: 6.30, 95% CI: 1.48\u201326.80, p = 0.032), while no significant associations were found for OATP1B1 variants. We conclude that OATP1B3 c.699G&gt;A is a potent predictor of OPrD-induced hyperbilirubinemia. Identifying this genotype pre-treatment allows clinicians to anticipate transient, benign bilirubin elevations and prevent unnecessary drug discontinuation, thereby mitigating therapeutic inertia and ensuring treatment continuity for CHC patients.<\/jats:p>","DOI":"10.3390\/cimb48050452","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T15:09:33Z","timestamp":1777388973000},"page":"452","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["OATP1B3 c.699G&gt;A Predicts a 6.3-Fold Increased Risk of Hyperbilirubinemia During OPrD Therapy for HCV"],"prefix":"10.3390","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9805-6624","authenticated-orcid":false,"given":"Zuhal","family":"Altintas","sequence":"first","affiliation":[{"name":"Department of Medical Genetics, Faculty of Medicine, Mersin University, 33343 Mersin, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Engin","family":"Altintas","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Faculty of Medicine, Mersin University, 33343 Mersin, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"6398","DOI":"10.3748\/wjg.v19.i38.6398","article-title":"New insights in bilirubin metabolism and their clinical implications","volume":"19","author":"Sticova","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1172\/JCI112946","article-title":"Influence of Cl- on organic anion transport in short-term cultured rat hepatocytes and isolated perfused rat liver","volume":"79","author":"Wolkoff","year":"1987","journal-title":"J. Clin. Investig."},{"key":"ref_3","first-page":"E638\u2013648","article-title":"Role of ligandin in transfer of bilirubin from plasma into liver","volume":"236","author":"Wolkoff","year":"1979","journal-title":"Am. J. Physiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"115039","DOI":"10.1016\/j.taap.2020.115039","article-title":"Elucidation of OATP1B1 and 1B3 transporter function using transgenic rodent models and commonly known single nucleotide polymorphisms","volume":"399","author":"Choudhuri","year":"2020","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"9626","DOI":"10.1074\/jbc.M004968200","article-title":"Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6","volume":"276","author":"Cui","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_6","unstructured":"Pyeritz, R., Korf, B., and Grody, W. (2019). Bile pigment metabolism and its disorders. Emery and Rimoin\u2019s Principles and Practice of Medical Genetics and Genomics: Cardiovascular, Respiratory, and Gastrointestinal Disorders, Elsevier. [7th ed.]."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1172\/JCI59526","article-title":"Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver","volume":"122","author":"Stranecky","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_8","first-page":"5252","article-title":"Down-regulation of OATP1B proteins correlates with hyperbilirubinemia in advanced cholestasis","volume":"8","author":"Sticova","year":"2015","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1310\/hpj5005-396","article-title":"Ombitasvir\/Paritaprevir\/Ritonavir and Dasabuvir","volume":"50","author":"Cada","year":"2015","journal-title":"Hosp. Pharm."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.cbi.2004.08.008","article-title":"Inhibition of human organic anion transporting polypeptide OATP 1B1 as a mechanism of drug-induced hyperbilirubinemia","volume":"150","author":"Campbell","year":"2004","journal-title":"Chem. Biol. Interact."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"T\u00e1trai, P., and Krajcsi, P. (2020). Prediction of Drug-Induced Hyperbilirubinemia by In Vitro Testing. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12080755"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1080\/00498254.2019.1629043","article-title":"Genetic polymorphisms of human hepatic OATPs: Functional consequences and effect on drug pharmacokinetics","volume":"50","author":"Nie","year":"2020","journal-title":"Xenobiotica"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.jhep.2019.07.020","article-title":"Real-life effectiveness and safety of sofosbuvir\/velpatasvir\/voxilaprevir in hepatitis C patients with previous DAA failure","volume":"71","author":"Degasperi","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1093\/hmg\/ddp202","article-title":"Genome-wide association meta-analysis for total serum bilirubin levels","volume":"18","author":"Johnson","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"ref_15","first-page":"e82213","article-title":"The Impact of Organic Anion-Transporting Polypeptide (OATP) Variants on the Side Effects of Direct-Acting Antivirals in Hepatitis C Patients","volume":"17","author":"Altintas","year":"2025","journal-title":"Cureus"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"18063","DOI":"10.1038\/s41598-018-36212-7","article-title":"OATP1B3 (699G>A) and CYP2C9*2, *3 significantly influenced the transport and metabolism of glibenclamide and glipizide","volume":"8","author":"Yang","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1021\/mp4001348","article-title":"Evaluating the in vitro inhibition of UGT1A1, OATP1B1, OATP1B3, MRP2, and BSEP in predicting drug-induced hyperbilirubinemia","volume":"10","author":"Chang","year":"2013","journal-title":"Mol. Pharm."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1476-5381.2009.00430.x","article-title":"Impact of OATP transporters on pharmacokinetics","volume":"158","author":"Kalliokoski","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jcmgh.2023.04.007","article-title":"Organic Anion Transporting Polypeptide (OATP) 1B3 is a Significant Transporter for Hepatic Uptake of Conjugated Bile Acids in Humans","volume":"16","author":"Pan","year":"2023","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s40265-015-0412-z","article-title":"Ombitasvir\/Paritaprevir\/Ritonavir Plus Dasabuvir: A Review in Chronic HCV Genotype 1 Infection","volume":"75","author":"Deeks","year":"2015","journal-title":"Drugs"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1203\/01.PDR.0000141846.37253.AF","article-title":"Risk factors for severe hyperbilirubinemia in neonates","volume":"56","author":"Huang","year":"2004","journal-title":"Pediatr. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jped.2013.01.008","article-title":"The impact of SLCO1B1 genetic polymorphisms on neonatal hyperbilirubinemia: A systematic review with meta-analysis","volume":"89","author":"Liu","year":"2013","journal-title":"J. Pediatr."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Atasilp, C., Kanjanapipak, J., Vichayaprasertkul, J., Jinda, S., Khemawoot, P., Rochanawutanon, M., Tanomsri, P., and Sukasem, C. (2022). Associations between UGT1A1 and SLCO1B1 polymorphisms and susceptibility to neonatal hyperbilirubinemia in Thai population. BMC Pediatr., 22.","DOI":"10.1186\/s12887-022-03311-4"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/sj.clpt.6100011","article-title":"Variants in the SLCO1B3 gene: Interethnic distribution and association with paclitaxel pharmacokinetics","volume":"81","author":"Smith","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1093\/hmg\/ddp203","article-title":"Common variants in the SLCO1B3 locus are associated with bilirubin levels and unconjugated hyperbilirubinemia","volume":"18","author":"Sanna","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1016\/j.xphs.2017.04.053","article-title":"Effect of Liver Disease on Hepatic Transporter Expression and Function","volume":"106","author":"Thakkar","year":"2017","journal-title":"J. Pharm. Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41586-020-2308-7","article-title":"The mutational constraint spectrum quantified from variation in 141,456 humans","volume":"581","author":"Karczewski","year":"2020","journal-title":"Nature"}],"container-title":["Current Issues in Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1467-3045\/48\/5\/452\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T15:51:49Z","timestamp":1777391509000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1467-3045\/48\/5\/452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":27,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["cimb48050452"],"URL":"https:\/\/doi.org\/10.3390\/cimb48050452","relation":{},"ISSN":["1467-3045"],"issn-type":[{"value":"1467-3045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]}}}